Alamar Biosciences Posts 82% Revenue Surge on Strong Consumable Demand
Event summary
- $29.4M Q2 revenue, up 82% YoY, driven by 147% growth in consumable sales.
- Launched eMTBR-tau immunoassay and NULISAseq™ Immune 340 Panel.
- Expanded dataset partnership to over 140,000 samples with Alzheimer's Disease Data Initiative and Gates Ventures.
- Raised full-year revenue guidance to $116M–$120M (59% growth).
- $13.2M net loss in Q2, wider than prior year due to increased R&D spending.
The big picture
Alamar's Q2 results highlight the accelerating demand for multiplexed proteomic tools in translational research. The company's strategic focus on scalable, non-invasive disease detection aligns with broader trends toward early diagnostic innovation. With $256M in cash reserves and expanding partnerships, Alamar is positioning itself as a key player in precision medicine—though execution risks remain amid aggressive R&D scaling.
What we're watching
- Revenue Sustainability
- Whether Alamar can maintain consumable revenue growth amid rising R&D costs.
- Market Expansion
- The pace at which new disease-area panels drive adoption beyond neuroscience.
- Competitive Positioning
- How Alamar's proteomics platform differentiates against traditional diagnostics.
Related topics